Howe & Rusling’s Asensus Surgical, Inc. ASXC Stock Holding History

Howe & Rusling’s Portfolio ASXC Stock Details ASXC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-77	Closed	–	–	1015
2020 Q3	$0	Buy	+77	New	+$30	﹤0.01%	882

Other funds holding ASXC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MCM

Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Howe & Rusling's ASXC Position: Q4 2020 in Review

Howe & Rusling sold out of Asensus Surgical, Inc. (ASXC) in Q4 2020, closing a stake of 77 shares.

Howe & Rusling first reported a position in ASXC in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 65 funds tracked by Wall St. Rank hold ASXC as of Q4 2020.

Howe & Rusling reported no remaining Asensus Surgical, Inc. position as of Q4 2020 after selling out during the quarter.
Howe & Rusling sold 77 Asensus Surgical, Inc. shares in Q4 2020.
Howe & Rusling first reported a position in Asensus Surgical, Inc. in Q3 2020 and held it in 1 quarter.
Howe & Rusling's Asensus Surgical, Inc. position peaked at $0 in Q3 2020.
65 funds tracked by Wall St. Rank held Asensus Surgical, Inc. as of Q4 2020.

Based on Howe & Rusling's 13F filing for Q4 2020, filed 8 Feb 2021.